Compare BCYC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | STRO |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.8M | 332.8M |
| IPO Year | 2019 | 2018 |
| Metric | BCYC | STRO |
|---|---|---|
| Price | $4.01 | $18.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $13.90 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 265.8K | 261.7K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.75 | $0.72 |
| 52 Week High | $9.16 | $43.85 |
| Indicator | BCYC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 30.17 |
| Support Level | $3.87 | $10.34 |
| Resistance Level | $4.21 | $26.35 |
| Average True Range (ATR) | 0.18 | 1.12 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 1.03 | 3.39 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.